Eligibility for Keytruda treatment depends on several factors, including the specific type of cancer, the presence of certain biomarkers, and the overall health of the patient. For instance, patients with high levels of PD-L1 expression or those with MSI-H or dMMR (deficient mismatch repair) tumors may be more likely to benefit from Keytruda. A comprehensive examination and diagnostic tests are necessary to determine eligibility.
